Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma

Annals of Oncology

Volumn 18, Issue 7, 2007, Pages 1209-1215

  Plonquet, A ^a   Haioun, C ^b   Jais, J P ^c   Debard, A L ^d   Salles, G ^e   Bene, M C ^f   Feugier, P ^g   Rabian, C ^c   Casasnovas, O ^h   Labalette, M ⁱ   Kuhlein, E ^j   Farcet, J P ^a   Emile, J F ^k   Gisselbrecht, C ^c   Delfau Larue, Marie Helene ^a,l  

^a INSERM   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e HOSPICES CIVILS DE LYON   (France)

^f CHU NANCY BRABOIS   (France)

^g UNIVERSITÉ DE LORRAINE   (France)

^h DIJON UNIVERSITY HOSPITAL   (France)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j CHU RANGUEIL   (France)

^k LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^l HENRI MONDOR HOSPITAL   (France)

more..

Author keywords

Diffuse large B cell lymphoma; Lymphopenia; NK cells; Prognosis

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BLEOMYCIN; CARMUSTINE; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINDESINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; FLOW CYTOMETRY; HAZARD RATIO; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NATURAL KILLER CELL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TUMOR IMMUNITY; UNIVARIATE ANALYSIS;

EID: 34547840267     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm110     Document Type: Article

References (33)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-3918.
2. Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: Who has "high-risk" disease. Blood 1994; 83: 1165-1173.
3. Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: Moving toward a molecularly targeted approach. Blood 2005; 15(106): 1164-1174.
4. Lossos IS, Morgensztem D. Prognostic biomarkers in diffuse large B-Cell lymphoma. J Clin Oncol 2006; 24: 995-1007.
5. Rimsza LM, Roberts RA, Miller TP et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumour immunosurveillance and poor patient survival regardless of other prognostic factors: A follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2004; 103: 4251-4258.
6. Rosenwald A, Wright G, Chan WC et al. Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.
7. Ansell SM, Stenson M, Habermann TM et al. CD4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol 2001; 19: 720-726.
8. Muris JJ, Meijer CJ, Cillessen SA et al. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia 2004; 18: 589-596.
9. Haioun C, Mounier N, Emile JF et al. Rituximab vs observation after High-Dose Consolidative First-Line Chemotherapy(HDC) with autologous stem cell transplantation in poor risk diffuse large B-cell lymphoma Final analysis of the LNH98-B3 GELA Study [ASH Annual Meeting Abstracts]. Blood 2005: 106 (Abstr 677).
10. Cheson BD, Horning SJ, Colffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
11. Whitby L, Granger V, Storie I et al. Quality control of CD4+ T-lymphocyte enumeration: Results from the last 9 years of the United Kingdom national external quality assessment scheme for immune monitoring (1993-2001). Cytometry 2002; 50: 102-110.
12. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. Springer Series in Statistics. New York, NY: Springer 2001; 568.
13. Gentleman R, Ihaka R. Lexical scope and statistical computing. J Comput Graph Stat 2000; 9: 491-508.
14. Bisset LR, Lung TL, Kaelin M et al. Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland. Eur J Haematol 2004; 72: 203-212.
15. Richards JO, Chang X, Blaser BW et al. Tumor growth impedes natural-killer-cell maturation in the bone marrow. Blood 2006; 108: 246-252.
16. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced hodgkin's disease. N Engl J Med 1998; 339: 1506-1514.
17. de Andrea ML, de Camargo B, Correa Alves A et al. Factors of prognostic importance in childhood non-Hodgkin's lymphoma treated with two modified LSA2-L2 protocols. A multivariate analysis approach. Cancer 1988; 62: 240-250.
18. Cabanillas F, Burke JS, Smith TL et al. Factors predicting for response and survival in adults with advanced non-Hodgkin's lymphoma. Arch Intern Med 1978; 138: 413-418.
19. Ray-Coquard I, Ghesquiere H, Bachelot T et al. ELYPSE Study Group. Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer 2001; 85: 816-822.
20. Dumontet C, Mounier N, Munck JN et al. Factors predictive of early death in patents receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: A GELA study. Br J Haematol 2002; 118: 210-217.
21. Wright CE, Erblich J, Valdimarsdottir HB, Bovbjerg DH. Poor sleep the night before an experimental stressor predicts reduced NK cell mobilization and slowed recovery in healthy women. Brain Behav Immun 2006; 358-363.
22. Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res 2003; 90: 127-156.
23. Street SE, Hayakawa Y, Zhan Y et al. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gamma delta T cells. J Exp Med 2004; 199 (6): 879-884.
24. Obeid M, Tesniere A, Ghiringhelli F et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13 (1): 54-61.
25. Ghiringhelli F, Menard C, Terme M et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 200517; 202 (8): 1075-1085.
26. Albertsson PA, Basse PH, Hokland M et al. NK cells and the tumour microenvironment: Implications for NK-cell function and anti-tumour activity. Trends Immunol 2003; 24: 603-609.
27. Monti S, Savage KJ, Kutok JL et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105: 1851-1861.
28. Ferlazzo G, Thomas D, Lin SL. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell lg-like receptors and become cytolytic. J Immunol 2004; 172 (3): 1455-1462.
29. Dalbeth N, Gundle R, Davies RJ et al. CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J Immunol 2004; 173 (10): 6418-6426.
30. Cooper MA, Fehniger TA, Turner SC et al. Human natural killer cells: A unique innate immunoregulatory role for the CD56 (bright) subset. Blood 2001; 97 (10): 3146-3151.
31. Costello RT, Fauriat C, Sivori S et al. NK cells: Innate immunity against hematological malignancies? Trends Immunol 2004; 25: 328-333.
32. Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 2004; 23: 255-259.
33. Cheson BD. Monoclonal antibody therapy for B-cell malignancies. Semin Oncol 2006; 33: S2-S14.